Company Analysis

Change Agents Corporation (CHGA)

Nasdaq: CHGA · Services-Computer Programming Services · Freehold, NJ · filing with the SEC since 2015
Grade3.5
◀ Past 3.0● Present 2.3▶ Future 4.9
2 est.

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

3 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Change Agents Corporation’s names, not what it holds today.

Patents granted
3
3 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against 1 in 2024 and 1 in 2023
Applications published
7
since 2001, to Dec 31, 2025
Names they are printed under
2
a former name
By yearGrantedApplications published
'21'22'23'24
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Avalon GloboCare Corp. a former name
named as the applicant on its applications, in US
0 granted
7 published
Avalon GloboCare Corp. a former name
US, as the owner printed on each patent
3 granted
0 published
Names not counted (2)
GLOBAL TECHNOLOGIES CORP
Most of its patents print KR; this name counts in US. 16 granted and 15 published under it are not counted.
GLOBAL TECHNOLOGIES CORP
Most of its patents print KR; this name counts in US. 0 granted and 17 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Mar 26, 202411,939,368QTY Fc fusion receptor proteinsPharmaceuticalsAvalon GloboCare Corp.
Jan 17, 202311,555,060QTY FC fusion water soluble receptor proteinsBiotechnologyAvalon GloboCare Corp.
Aug 2, 202211,401,320QTY FC fusion receptor proteinsPharmaceuticalsAvalon GloboCare Corp.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 2, 20232023/0348556ARTIFICIAL IMMUNOSURVEILLANCE CHIMERIC ANTIGEN RECEPTOR AND CELLS EXPRESSING THE SAMEMedical technologyAvalon GloboCare Corp.
Aug 24, 20232023/0265164QTY FC Fusion Water Soluble GPCR ProteinsBiotechnologyAvalon GloboCare Corp.
Apr 20, 20232023/0124436QTY FC FUSION RECEPTOR PROTEINSPharmaceuticalsAvalon GloboCare Corp. · patent 11,939,368 granted from it
Feb 3, 20222022/0031836EMULSOMES COMPRISING S-LAYER FUSION PROTEINS AND METHODS OF USE THEREOFPharmaceuticalsAvalon GloboCare Corp.
Dec 30, 20212021/0403509S-LAYER VACCINE FUSION PROTEINS AND METHODS OF USEPharmaceuticalsAvalon GloboCare Corp.
Oct 7, 20212021/0309720QTY FC Fusion Receptor ProteinsPharmaceuticalsAvalon GloboCare Corp. · patent 11,401,320 granted from it
Sep 30, 20212021/0300993QTY FC FUSION WATER SOLUBLE RECEPTOR PROTEINSBiotechnologyAvalon GloboCare Corp. · patent 11,555,060 granted from it

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CHGA · research, not advice